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Response Modification in Carcinogenesis
by Peter A. Cerutti*
A major goal in multistep carcinogenesis research is the integration ofrecent findings obtained by sophisti-
cated molecular-genetic and cytogenetic analysis ofcancer into the more descriptive concepts ofexperimental
pathology. It isproposed thatthe creation ofapromotable cell incarcinogenic initiation requires aresponse
modification to extracellular or intercellular signals. Different types ofresponse modification can be dis-
tinguished: changes in the receptors for growth and differentiation factors and their cytoplasmic and nu-
clear signal transduction pathways; increased resistance ofinitiated cells to cytotoxic agents; alterations
injunctional cell-to-cell communications. The challenge ofa response-modified cell to an appropriate pro-
moter results in its selection and clonal expansion,usually to a benign tumor. In addition, for malignancy,
chromosomal changes are required that affectcellular functions that can play a roleearly orlate in tumori-
genesis. These concepts are illustrated with examples from oncogene research and oxidant promotion.
Introduction
Over the last few years the question has arisen in car-
cinogenesis research of how to relate new findings ob-
tained with sophisticated cytogenetic and molecular bi-
ologicalmethods to the morephenomenological results of
experimental pathology. Important questions are: What
are the functional implications of clonal cytogenetic
changes? What is the role ofthe activation ofparticular
protooncogenes inmultistep carcinogenesis? Whatis the
relationship of these events to the classical concepts of
multistage carcinogenesis: initiation, promotion, progres-
sion?
The stages in carcinogenesis are more readily defined
by the end points that are reached than by the mecha-
nisms and agents that accomplish the individual steps.
The majorresult ofinitiation isthe creationofapromota-
ble cell. This requires a response modification to extra-
orintercellular signals that distinguishes the initiated cell
from the rest ofthe tissue. A response modification re-
mains phenotypically unexpressed until the tissue is
challenged by apromoter. The major result ofpromotion
is the clonal expansion of the response-modified cell by
a variety ofmechanisms and agents that depend on the
characteristics oftheinitiating responsemodification and
onthe tissue. Ingeneral, response modification andclonal
expansion alone do not suffice for the development of a
malignant tumor. Additional specific chromosomal
changes are required that can occur early, before or af-
ter response modification, or later after some clonal ex-
pansion has occurred. We can speculate that response
modifications in carcinogenic initiation often result from
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the action of mutagens, whereas chromosomal aberra-
tions are more likelyinducedbyclastogenic agents. Itis
evident that two majorgoals in carcinogenesis research
arethe characterization infunctionalandmolecular terms
ofdifferent forms ofresponse modification and ofpoten-
tially malignant chromosomal aberrations.
Promotion accomplishes the clonal expansion/selection
(1,2) of response-modified cells by a variety of mecha-
nisms and agents. Therefore, it is misleading to define
promotion around the pharmacological properties of a
specific class ofpromoters such asthephorbol esters. Al-
though there may exist ideal endogenous promoters, we
cannot expect to find xenobiotics thatpossess exclusively
promoting activity. The complexity is illustrated if one
considers afour-step carcinogenesis model: chromosomal
alteration, responsemodification, promotion, progression.
Six quality permutations are possible for a carcinogen
thatpossesses two properties (e.g., acompound couldbe
a strong clastogen plus a strong progressor, a strong
clastogen plus a strong promoter, etc.).
Of course, promoters act on an entire tissue, i.e.,
response-modified, initiated epithelial cells, normal
epithelial cells, stromal cells, inflammatory leukocytes,
etc. Promoters interactwith the target cells themselves
or disturb short- and long-range cellular interactions.
Short-range interactions may involve cell-cell communi-
cations, long-range interactions, the disturbance ofpara-
crine signals, and the production of clastogenic factors.
Individual promoters are expected to affect multiple cel-
lularandmolecularmechanisms. Onlypart ofthesemay
contribute to the promotional effect (but this does not
meanthatthose otherreactions are irrelevant). Abetter
understanding of the cellular response systems to ex-
ogenous signalsis aprerequisite fortheunravellingofthe
complexpharmacology ofspecific xenobiotic promoters.P A. CERUTTI
Mechanisms of Response
Modification Involving Changes in
Signal Transduction and Gene
Expression
There is much evidence from oncogene research for re-
sponse modifications that involve changes in growth or
differentiation factors, their receptors, and cytoplasmic
and nuclear signal transduction. Several of the virally
related protooncogene products are components ofpath-
ways that transmit extracellular signals to the genome
(3,4). Candidates forprotooncogenes with apotential role
as response modifiers are ras, src, tck, abl, (erbA) with
membrane or cytoplasmic functions, and myc, myb,jun,
andfos with nuclear functions. The following comments
focus on ras, myc, and fos. These examples of virally
related protooncogenes were chosen because they allow
mechanistic insights. Undoubtedly, additional genes with
the potential to participate in response modifications re-
main to be identified.
The activation of a ras gene by a point mutation rep-
resents the prototype of a response modification. It ap-
pears to participate in the development ofseveral forms
of human cancer (5-8). The ras gene product is a 21 kD
G-type protein that plays a fundamental role in mem-
brane signal transduction (3,9). Not surprisingly, its ac-
tivation by apoint mutation can sufficiently disturb sig-
nal transduction to affect the regulation of cellular
differentiation and proliferation. Indeed, there are
several examples where the transfection of v-ras or ac-
tivated c-ras into epithelial cells disturbed or blocked
their terminal differentiation (10-13). In fibroblastic cells,
ras-activation increased their sensitivity to stimulation
by growth factors (14-17).
Changes in the expression of c-myc can form the basis
foranothertype ofresponse modification. c-myc codes for
a nuclear protein that plays a role in DNA replication
(18-20). Its early induction appears to be required in the
recruitment of quiescent cells to competence and cell
proliferation. In epithelial cells the persistent (over)ex-
pression of c-myc and aloss of myc downregulation may
be incompatible with terminal differentiation (21-24). A
lack ofthe responsiveness ofmyc expression to extracel-
lular signals has been observed in premalignant and
malignant cells(25). As was the case for ras, overexpres-
sion of c-myc infibroblastic cells increased their response
to growth factors (17,19,26).
The deregulation of the expression of the protoon-
cogene c-fos represents a third case of response modifi-
cation in carcinogenesis. c-fos codes for anuclearprotein
that participates in the regulation of gene expression.
c-fos is induced immediately by multiple stimuli (27,28).
The fact that c-fos expression is regulated by several
genetic mechanisms (29-33) attests to its fundamental im-
portance in formulating at the proximal end the cellular
response to extracellular signals.
Thefos protein possesses DNAbindingproperties. At
least in one case, the regulation ofthe aP2 gene in adipo-
cyte differentiation, the binding ofthefos protein to an
upstream regulatory sequence has been directly demon-
strated (34). Its activity is modulatedbyposttranslational
phosphorylation (35)andpossiblyothersubstitutionreac-
tions.
There are several examples where a disburbance of
c-fos expression has been observed in association with
malignant transformation. In transformed, differentia-
tion-resistantmouse epidermal cells RBK, thephorbol es-
terpromoter TPAfailed to induce c-fos (25). Similarly, ac-
tive oxygengenerated by xanthine/xanthine oxidase only
weaklyinduced c-fos inpromotable mouse epidermal cells
JB6 clone 41 in contrast to the nonpromotable clone 30
(36).
Response Modification to Cytostatic
Agents in Rat Liver Carcinogenesis
Response modification as a consequence of initiation
can consistofthe acquisition ofincreasedresistanceto en-
dogenous or xenobiotic cytostatic/cytotoxic agents. In
proliferating tissues the selective resistance of the
response-modified cell to the cytostatic/cytotoxic pro-
moter can suffice for clonal selection, while in nonreplicat-
ing tissues, general growth stimulation may be required
in addition. The most convincing examples of response
modification in the form ofincreased resistance to xenobi-
otic carcinogens derive from experimental liver carcino-
genesis. In the resistant hepatocyte model of Solt and
Farber (37), the following protocol leads to potentially
malignant nodules. Treatment with an initiating carcino-
gen(e.g., diethylnitrosamine) isfollowed by the exposure
to a low, noninitiating dose of a cytotoxic agent (e.g.,
2-acetylaminofluorine), and growth is stimulated by par-
tial hepatectomy or CC14. Otherprotocols related to the
resistant hepatocyte model have been developed by
several researchers (38,39). Considerable experimental
evidence supports thefollowinginterpretation. Initiation
has generated a rare hepatocyte with increased resis-
tance to growth inhibition by several classes of xenobi-
otics or dietary deficiencies. This allows the preferential
growth ofinitiated cells in a cytostatic/cytotoxic environ-
ment that suppresses the proliferation ofthe majority of
hepatocytes.
Response Modification to Cytotoxic
Oxidants in Mouse Skin Tumor
Promotion
The evidence is convincing that oxidants and agents
thatinduce a cellularprooxidant state can act as carcino-
gens, in particular as promoters andprogressors (30-46).
Bona fide oxidants with promotional activity include
H202, superoxide, ozone, hyperbaric oxygen, peroxya-
cetic acid, chlorobenzoic acid, benzoyl peroxide, cumene
hydroperoxide, p-nitro-perbenzoic acid, and periodate
(47,48). Infiltratedphagocytes represent a major source
ofoxidants in inflamed tissues (49, 50), and in several in-
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FIGURE 1. Scheme ofthe multiple cellular reactions that play a role in tumor promotion by extracellular oxidants.
stancesinflammation appears tobe aprerequisite forpro-
motion (51-53). Oxidant promoters induce DNA strand
breakage (54-58). DNAbreaks elicit secondarymetabolic
reactions, in particular poly ADP-ribosylation of chro-
mosomal proteins (59). At low oxidant concentrations,
moderate levels of poly ADP-ribosylation may affect
chromatin conformation andfunction. High oxidant con-
centrations may result in excessive poly ADP-
ribosylation, NAD and ATP depletion, inhibition ofmac-
romolecular synthesis, and eventually cell death (60-62).
A subtle balance between the induction ofgrowth-related
genes and cytostatic effects may have to be attained for
the promotion of initiated cells by oxidants.
Our work with xanthine/xanthine oxidase as an ex-
tracellular source ofactive oxygen(AO) andpromotable
(clone 41) andnonpromotable (clone 30) mouse epidermal
cells JB6 allow insights into the mechanism of action of
oxidant promoters. We found that AO stimulated the
growth only ofpromotable clone 41 after an initial period
ofmoderate inhibition, butitwas strongly cytostatic for
nonpromotable clone 30. We alsofound thatAO induced
larger amounts of DNA strand breaks and poly ADP-
ribosylation of chromosomal proteins in nonpromotable
cells in reactions that required intracellular Fe and Ca2+.
Excessive DNA strand breakage and poly ADP-
ribosylation may contribute to the cytostatic effectofAO
(63). Apossible reason forthe differences between these
two clones was discovered when we compared the con-
stitutive levels ofthe activities, protein concentrations,
and mRNA levels for the antioxidant enzymes catalase
(CAT), Cu, Zn-superoxide dismutase (SOD), and
glutathione-peroxidase (GPx). We found that CAT and
SOD (but not GPx) levels were 2- to 3-fold higher in the
promotable clone 41. We propose that promotable cells
possess aresponse modification inthe form ofa superior
antioxidant defense that protects them from excessive
cytostatic effects ofAO.
Asexemplifiedbythe action ofpolypeptidegrowth fac-
tors andphorbol esterpromoters, growth stimulation(or
arrest) requires the modulation of the expression of
numerous genes. AO was capable ofinducingthegrowth-
and differentiation-related protooncogenesfos and myc
in promotable and nonpromotable JB6 cells. We specu-
late that these genes can exerttheirfunctionsonlyinthe
promotable clone 41 because thegeneral cytostatic effects
ofAO are moderate (36,63). Ourresults suggest thatAO
may act as a mediator and activate signal transduction
pathways that ultimately modulate the expression ofim-
mediate early genes such asfos and myc as do the phor-
bol ester TPA, serum, and certain polypeptide growth
factors. Figure 1 shows a scheme ofthe multiple cellular
reactionsthatplay arole intumorpromotionbyextracel-
lular oxidants.
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